Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Kastle Therapeutics, LLC today announced that Kastle has acquired global rights to develop and commercialize KYNAMRO (mipomersen sodium) injection. KYNAMRO is approved in the United States for use in patients with homozygous familial hypercholesterolemia (HoFH) to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), total cholesterol (TC) and non-high density lipoprotein-cholesterol (non-HDL-C) as an adjunct to lipid lowering medications and diet. See the following link for the full press release:
Additionally, BioSolutia, Inc. with corporate offices in Lake Mary FL announced that its Pharmaceutical Services Division has been chosen by Kastle to manage the Kynamro Cornerstone Program which provides a variety of reimbursement and support services for patients taking KYNAMRO. “We are proud to have been chosen to provide strategic consulting and support services for Kastle’s first product acquisition and look forward to a successful collaboration” said Jim Long, Principal & Co-Founder of BioSolutia. “Since 2004 our team has helped patients and their families taking specialty pharmaceuticals and orphan drugs, and we look forward to utilizing that expertise to support patients taking KYNAMRO” added Dan Desmarais, Principal & Co-Founder of BioSolutia.